Future Horizons: Development, Top Players, Share, and Size in the Base Editing Market - Forecasting to 2028
In May 2023, Revvity entered into a license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.
View full press release